William Blair initiated coverage of Lenz Therapeutics with an Outperform rating. Lenz is an emerging leader in eye care, developing the “best-in-class” therapy for the treatment of presbyopia, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz Therapeutics initiated with a Buy at Citi
- LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
- Lenz Therapeutics announces results from Phase 3 CLARITY study
- Lenz Therapeutics initiated with an Overweight at Piper Sandler
- Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics
